Multiple trials arer going on hydroxychloroquine (HCQ) for the treatment of COVID-19. HCQs are comparatively safer drug while used for rheumatoid arthritis and their potential toxicity is well known. But now clinicians have found reports regarding its different sort of complications. HCQ s related retinal toxicity is apparently a significant one and the risk factors for the development are a high dose relative to real weight and duration of use.
For more information: https://www.medscape.com